Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Worg Pharma Completes $57 Million Series B for Novel Allergy and Autoimmune Therapies

publication date: Sep 14, 2022

Shanghai Worg Pharma completed a $57 million Series B financing to advance clinical trials of its lead products and build its leadership team. Worg has two innovative technology platforms, both acquired from other companies, that have developed clinical-stage products: PCFiT for allergy vaccines and Apitope (antigen processing independent epitopes) that directly target the immunological basis of autoimmune diseases. In 2020, Worg closed a deal with Biomay, an Austrian company, for its PCFiT platform and its five allergy candidates. One year ago, Worg bought Apitope and its four immunotherapy candidates for autoimmune diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital